Valiant Capital Partners has made a big bet on Eli Lilly.
The drug giant is currently the largest long equity position of the Tiger Grandcub, accounting for 8.66 percent of the firm’s capital, according to the third-quarter letter, which was obtained by Institutional Investor.
In
